<DOC>
	<DOCNO>NCT01186991</DOCNO>
	<brief_summary>This randomize , Phase II , double-blind , multicenter , placebo-controlled trial design preliminarily estimate efficacy evaluate safety tolerability onartuzumab ( MetMAb ) + bevacizumab + paclitaxel onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel participant metastatic locally recurrent , triple-negative breast cancer either receive treatment ( first-line ) progress one conventional cytotoxic chemotherapy regimen ( second-line ) .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Onartuzumab And/or Bevacizumab Combination With Paclitaxel Participants With Metastatic , Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Histologically confirm estrogen receptor ( ER ) , progesterone receptor ( PR ) , human epidermal growth factor 2 ( HER2 ) negative ( triplenegative ) adenocarcinoma breast Confirmed availability tumor tissue Prior therapy two regimen metastatic breast cancer Any systemic anticancer therapy within 3 week prior Day 1 Cycle 1 Major surgical procedure , open biopsy , significant traumatic injury within 30 day prior Day 1 Cycle 1 Prior therapy taxane metastatic breast cancer Prior therapy bevacizumab , sorafenib , sunitinib , putative vascular endothelial growth factor ( VEGF ) pathwaytargeted therapy follow diagnosis breast cancer Prior therapy hormone and/or trastuzumab Inadequate hematology , renal , hepatic organ function Bevacizumab Uncontrolled hypertension ( systolic pressure great [ &gt; ] 150 millimeter mercury [ mmHg ] and/or diastolic pressure &gt; 100 mmHg ) , without antihypertensive medication Evidence bleed diathesis coagulopathy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>